pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
230
stories
9d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
9d
STAT+: European regulators take steps to bolster clinical trial transparency
stat
9d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
9d
FDA panel confronting peptide controversy
stat
9d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
9d
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
biospace
9d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
9d
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
9d
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
9d
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
9d
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
endpoints
9d
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
9d
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
9d
Make or break: Commercial hires critical for success
biospace
9d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
9d
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
10d
Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's prevention
endpoints
10d
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
10d
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
10d
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
10d
AI data becomes sticking point in biopharma dealmaking
biospace
10d
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
10d
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
11d
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
11d
Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’
biopharma dive
11d
STAT+: Anthropic deepens work with rare disease drugs
stat
11d
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
11d
Novartis stays 'geography-agnostic' in dealmaking amid flurry of China deals
biospace
11d
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
11d
STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
stat
← prev
page 2 of 8
next →
